Pascal Vranckx1, Sergio Leonardi2, Matteo Tebaldi3, Simone Biscaglia3, Giovanni Parrinello4, Sunil V Rao5, Roxana Mehran6, Marco Valgimigli7. 1. Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Hasselt, Belgium Department of Cardiology, Thoraxcentre, Erasmus Medical Center, Rotterdam, The Netherlands Thoraxcentre, Erasmus Medical Center, Rotterdam, The Netherlands. 2. Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy. 3. Department of Cardiology, University of Ferrara, Ferrara, Italy. 4. Medical Statistics Unit, University of Brescia, Brescia, Italy. 5. The Duke Clinical Research Institute, Durham, NC, USA. 6. Mount Sinai School of Medicine, New York, NY, USA. 7. Thoraxcentre, Erasmus Medical Center, Rotterdam, The Netherlands m.valgimigli@erasmusmc.nl vlgmrc@unife.it.
Abstract
AIMS: The Bleeding Academic Research Consortium (BARC) classification has been proposed by consensus to standardize bleeding endpoint definition and reporting in cardiovascular clinical trials. There are no prospective studies on its prognostic impact. METHODS AND RESULTS: We explored the association of BARC-defined bleeding with mortality and compared its prognostic value against two validated bleeding scales: the Thrombolysis in Myocardial Infarction (TIMI) and the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) scales. Non-coronary artery bypass graft (CABG)-related bleedings within the PRODIGY trial were prospectively adjudicated by a blinded Clinical Event Committee and analysed according to multiple statistical modelling. At 2 years, bleeding occurred in 143 patients (7.1%) according to BARC Type 2, 3, or 5; in 50 patients (2.5%) according to TIMI minor or major; and in 61 patients (3.1%) according to GUSTO moderate or severe. One hundred sixty-three patients died (8.1%). After multivariable modelling, BARC Type 2, 3, or 5 bleeding was associated with increased 2-year mortality [hazard ratio (HR): 3.77; 95% confidence interval (CI): 2.37-5.98]. Bleeding Academic Research Consortium Type 3 or 5 was associated with an increased mortality rate at 2 years (adjusted HR: 7.72; 95% CI: 4.75-12.54) similar to that provided by TIMI (HR: 7.64, 95% CI: 4.53-12.87) or GUSTO (HR: 7.36, 95% CI: 4.38-12.34) criteria. CONCLUSIONS: In a contemporary, all-comer percutaneous coronary intervention trial actionable BARC bleedings were associated with increased risk of mortality with BARC Type 3 or 5 bleedings providing a similar mortality risk to that posed by TIMI or GUSTO scales. Published on behalf of the European Society of Cardiology. All rights reserved.
RCT Entities:
AIMS: The Bleeding Academic Research Consortium (BARC) classification has been proposed by consensus to standardize bleeding endpoint definition and reporting in cardiovascular clinical trials. There are no prospective studies on its prognostic impact. METHODS AND RESULTS: We explored the association of BARC-defined bleeding with mortality and compared its prognostic value against two validated bleeding scales: the Thrombolysis in Myocardial Infarction (TIMI) and the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) scales. Non-coronary artery bypass graft (CABG)-related bleedings within the PRODIGY trial were prospectively adjudicated by a blinded Clinical Event Committee and analysed according to multiple statistical modelling. At 2 years, bleeding occurred in 143 patients (7.1%) according to BARC Type 2, 3, or 5; in 50 patients (2.5%) according to TIMI minor or major; and in 61 patients (3.1%) according to GUSTO moderate or severe. One hundred sixty-three patients died (8.1%). After multivariable modelling, BARC Type 2, 3, or 5 bleeding was associated with increased 2-year mortality [hazard ratio (HR): 3.77; 95% confidence interval (CI): 2.37-5.98]. Bleeding Academic Research Consortium Type 3 or 5 was associated with an increased mortality rate at 2 years (adjusted HR: 7.72; 95% CI: 4.75-12.54) similar to that provided by TIMI (HR: 7.64, 95% CI: 4.53-12.87) or GUSTO (HR: 7.36, 95% CI: 4.38-12.34) criteria. CONCLUSIONS: In a contemporary, all-comer percutaneous coronary intervention trial actionable BARC bleedings were associated with increased risk of mortality with BARC Type 3 or 5 bleedings providing a similar mortality risk to that posed by TIMI or GUSTO scales. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Amit P Amin; Tracy Y Wang; Lisa McCoy; Richard G Bach; Mark B Effron; Eric D Peterson; David J Cohen Journal: J Am Coll Cardiol Date: 2016-01-05 Impact factor: 24.094
Authors: Behnood Bikdeli; Thomas McAndrew; Aaron Crowley; Shmuel Chen; Ghazaleh Mehdipoor; Björn Redfors; Yangbo Liu; Zixuan Zhang; Mengdan Liu; Yiran Zhang; Dominic P Francese; David Erlinge; Stefan K James; Yaling Han; Yi Li; Adnan Kastrati; Stefanie Schüpke; Rod H Stables; Adeel Shahzad; Philippe Gabriel Steg; Patrick Goldstein; Enrico Frigoli; Roxana Mehran; Marco Valgimigli; Gregg W Stone Journal: Thromb Haemost Date: 2019-12-09 Impact factor: 5.249
Authors: Leia Hee; Oliver J Gibbs; Joseph G Assad; Lokesh D Sharma; Andrew Hopkins; Craig P Juergens; Sidney Lo; Christian J Mussap Journal: J Saudi Heart Assoc Date: 2019-05-31
Authors: Francesco Costa; Jan G Tijssen; Sara Ariotti; Sara Giatti; Elisabetta Moscarella; Paolo Guastaroba; Rossana De Palma; Giuseppe Andò; Giuseppe Oreto; Felix Zijlstra; Marco Valgimigli Journal: J Am Heart Assoc Date: 2015-12-07 Impact factor: 5.501